Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

FH mutation

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

›

FH mutation	Renal Cell Carcinoma	FH mutation	Renal Cell Carcinoma	nivolumab + cabozantinib tablet Sensitive: C3 – Early Trials nivolumab + cabozantinib tablet Sensitive : C3	nivolumab + cabozantinib tablet Sensitive: C3 – Early Trials nivolumab + cabozantinib tablet Sensitive : C3
FH mutation	Renal Cell Carcinoma	FH mutation	Renal Cell Carcinoma	Immunotherapy + Tyrosine kinase inhibitor Sensitive: C3 – Early Trials Immunotherapy + Tyrosine kinase inhibitor Sensitive : C3	Immunotherapy + Tyrosine kinase inhibitor Sensitive: C3 – Early Trials Immunotherapy + Tyrosine kinase inhibitor Sensitive : C3
FH mutation	Renal Cell Carcinoma	FH mutation	Renal Cell Carcinoma	bevacizumab + erlotinib Sensitive: C4 – Case Studies bevacizumab + erlotinib Sensitive : C4	bevacizumab + erlotinib Sensitive: C4 – Case Studies bevacizumab + erlotinib Sensitive : C4
FH mutation	Renal Cell Carcinoma	FH mutation	Renal Cell Carcinoma	pazopanib Sensitive: C4 – Case Studies pazopanib Sensitive : C4	pazopanib Sensitive: C4 – Case Studies pazopanib Sensitive : C4